Rosalind Kieran

Rosalind Kieran

Auto-generated profile, based on publicly available information

Rosalind Kieran

Medical Oncology Dept., CUH - Cork University Hospital, Cork, Ireland

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 February 2023 in Molecular Cancer Therapeutics
Verified
Journal Article
Open access
PDF file
BPBruno de Paula
Bruno de Paula
RKRosalind Kieran
Rosalind Kieran
SKSamantha Shui Yuan. Koh
Samantha Shui Yuan. Koh
SCSusanne Cancer Crocamo
Susanne Cancer Crocamo
EAEliana Saul Furquim Werneck Abdelhay
Eliana Saul Furquim Werneck Abdelhay
DMDaniel Muñoz-Espín
Daniel Muñoz-Espín
Triple-negative breast cancer (TNBC) is associated with an elevated risk of recurrence and poor prognosis. Historically, only chemotherapy was available as systemic treatment, but immunotherapy and targeted therapies currently offer prolonged benefits. TNBC is a group of diseases with heterogeneous treatment sensitivity, and resistance is inevitable and early for a large proportion of the intrinsic subtypes. Although senescence induction by anticancer therapy offers an immediate favorable clinical outcome once the rate of tumor progression reduces, these cells are commonly dysfunctional and metabolically active, culminating in treatment-resistant repopulation associated with worse prognosis. This heterogeneous response can also occur without therapeutic pressure in response to damage or oncogenic stress, playing a relevant role in the carcinogenesis. Remarkably, there is preclinical and exploratory clinical evidence to support a relevant role of senescence in treatment resistance. Therefore, targeting senescent cells has been a scientific effort in many malignant tumors using a variety of targets and strategies, including increasing proapoptotic and decreasing antiapoptotic stimuli. Despite promising results, there are some challenges to applying this technology, including the best schedule of combination, assessment of senescence, specific vulnerabilities, and the best clinical scenarios. This review provides an overview of senescence in TNBC with a focus on future-proofing senotherapy strategies.

1 November 2021 in JCO Precision Oncology
Verified
Journal Article
Closed access
RKRosalind Kieran
Rosalind Kieran
BPBruno de Paula
Bruno de Paula
MHMichael Hubank
Michael Hubank
ABAllanah Barker
Allanah Barker
APAnna L. Paterson
Anna L. Paterson
GDGary J. Doherty
Gary J. Doherty

4 May 2023
Verified
Other
Open access
BPBruno de Paula
Bruno de Paula
RKRosalind Kieran
Rosalind Kieran
SKSamantha Shui Yuan Koh
Samantha Shui Yuan Koh
SCSusanne Cancer Crocamo
Susanne Cancer Crocamo
EAEliana Saul Furquim Werneck Abdelhay
Eliana Saul Furquim Werneck Abdelhay
DMDaniel Muñoz-Espín
Daniel Muñoz-Espín
Examples of “one-two punch” strategy in TNBC.

20 October 2023 in Annals of Oncology
Verified
Journal Article
Closed access
RKR. Kieran
R. Kieran
KCKathryn E Coakley
Kathryn E Coakley
TCT. Cronin
T. Cronin
CWCatherine Sarah Weadick
Catherine Sarah Weadick
BMB. Macanovic
B. Macanovic
SOS. O'Reilly
S. O'Reilly

4 May 2023
Verified
Other
Open access
BPBruno de Paula
Bruno de Paula
RKRosalind Kieran
Rosalind Kieran
SKSamantha Shui Yuan Koh
Samantha Shui Yuan Koh
SCSusanne Cancer Crocamo
Susanne Cancer Crocamo
EAEliana Saul Furquim Werneck Abdelhay
Eliana Saul Furquim Werneck Abdelhay
DMDaniel Muñoz-Espín
Daniel Muñoz-Espín
Triple-negative breast cancer (TNBC) is associated with an elevated risk of recurrence and poor prognosis. Historically, only chemotherapy was available as systemic treatment, but immunotherapy and targeted therapies currently offer prolonged benefits. TNBC is a group of diseases with heterogeneous treatment sensitivity, and resistance is inevitable and early for a large proportion of the intrinsic subtypes. Although senescence induction by anticancer therapy offers an immediate favorable clinical outcome once the rate of tumor progression reduces, these cells are commonly dysfunctional and metabolically active, culminating in treatment-resistant repopulation associated with worse prognosis. This heterogeneous response can also occur without therapeutic pressure in response to damage or oncogenic stress, playing a relevant role in the carcinogenesis. Remarkably, there is preclinical and exploratory clinical evidence to support a relevant role of senescence in treatment resistance. Therefore, targeting senescent cells has been a scientific effort in many malignant tumors using a variety of targets and strategies, including increasing proapoptotic and decreasing antiapoptotic stimuli. Despite promising results, there are some challenges to applying this technology, including the best schedule of combination, assessment of senescence, specific vulnerabilities, and the best clinical scenarios. This review provides an overview of senescence in TNBC with a focus on future-proofing senotherapy strategies.

4 May 2023
Verified
Other
Open access
BPBruno de Paula
Bruno de Paula
RKRosalind Kieran
Rosalind Kieran
SKSamantha Shui Yuan Koh
Samantha Shui Yuan Koh
SCSusanne Cancer Crocamo
Susanne Cancer Crocamo
EAEliana Saul Furquim Werneck Abdelhay
Eliana Saul Furquim Werneck Abdelhay
DMDaniel Muñoz-Espín
Daniel Muñoz-Espín
Examples of senescence inducers in TNBC.